clinical trial · NCT07650266
A Study of Cemiplimab and Fianlimab in People With Nasopharyngeal Carcinoma
Nasopharyngeal CarcinomaNasopharyngeal CancerNasopharynx CarcinomaNasopharynx CancerCemiplimabFianlimab
brief summary
The purpose of this study is to find out whether cemiplimab, with or without fianlimab, is an effective treatment for advanced nasopharyngeal carcinoma (NPC), when given with standard chemotherapy drugs gemcitabine and cisplatin before standard chemoradiation.
started
Jul 1, 2026
primary completion
Jul 1, 2030
completion
Jul 1, 2030
last updated
Jun 16, 2026
official title
A Pilot Randomized Trial of Induction Cemiplimab With or Without Fianlimab in De-escalated Chemoradiation for Locoregionally Advanced Non-Metastatic Nasopharyngeal Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol